上原知也

研究者氏名	上原知也
	ウエハラトモヤ
URL	https://www.p.chiba-u.jp/lab/housha/
所属	千葉大学
部署	大学院薬学研究院創薬資源科学
職名	教授
J-Global ID	200901072574590930

研究キーワード

放射性医薬品 ,Radiopharmaceutical

研究分野

ライフサイエンス / 薬系分析、物理化学 /

経歴

2019年10月

現在

千葉大学大学院薬学研究院教授

論文

<1 234 5 >

Renal Handling of 99mTc-Labeled Antibody Fab Fragments with a Linkage Cleavable by Enzymes on Brush Border Membrane.

Tomoya Uehara Naoki Kanazawa Chie Suzuki Yuki Mizuno Hiroyuki Suzuki Hirofumi Hanaoka Yasushi Arano

Bioconjugate chemistry 31(11) 2618-2627 2020年11月

The high and persistent renal radioactivity levels after injection of radiolabeled low-molecular-weight polypeptides constitute a significant problem for their diagnostic and therapeutic applications, especially when they are labeled with metallic...

Aryl isocyanide derivative for one-pot synthesis of purification-free 99mTc-labeled hexavalent targeting probe

Yuki Mizuno Nagiho Komatsu Tomoya Uehara Yuka Shimoda Kohta Kimura Yasushi Arano Hiromichi Akizawa

Nuclear Medicine and Biology 86-87 30-36 2020年7月 [査読有り]

Manipulating Pharmacokinetics of Purification-Free 99mTc-Labeled Bivalent Probes for In Vivo Imaging of Saturable Targets.

Tomoya Uehara Ayaka Sensui Shiori Ishioka Yuki Mizuno Shiori Takahashi Hideaki Takemori Hiroyuki Suzuki Yasushi Arano

Molecular pharmaceutics 17(5) 1621-1628 2020年5月

The accumulation of 99mTc-labeled probes targeting saturable systems of the body is hindered by the presence of a large excess of unlabeled ligands needed to ensure high radiochemical yields in a short reaction time. To address the issue, we recen...

Full report on a survey of adverse reactions to radiopharmaceuticals from 1975 to 2017 in Japan.

Hiroshi Matsuda Tomoya Uehara Hidehiko Okazawa Sunao Mizumura Kunihiko Yokoyama Mana Yoshimura

Annals of nuclear medicine 34(4) 299-304 2020年4月

OBJECTIVE: This pharmacovigilance-based survey was aimed at determining the prevalence of, and association between, radiopharmaceuticals and adverse reactions to radiopharmaceuticals from 1975 to 2017 in Japan. METHODS: The Subcommittee for Safety...

Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models.

Taiki Kurino Reiko Matsuda Ayu Terui Hiroyuki Suzuki Tomomi Kokubo Tomoya Uehara Yasushi Arano Akihiro Hisaka Hiroto Hatakeyama

Journal for immunotherapy of cancer 8(1) 2020年2月

BACKGROUND: Recently, antiprogrammed cell death protein 1 (aPD-1) and antiprogrammed death-ligand 1 (aPD-L1) monoclonal antibodies (mAbs) have been approved. Even though aPD-1 and aPD-L1 mAbs target the same PD-1/PD-L1 axis, it is still unclear wh...